The meta-analysis by Riddle et al. in this issue of Clinical Infectious Diseases [1] focuses on the antidiarrheal drug loperamide hydrochloride and its efficacy when combined with antimicrobials to shorten illness in adults with traveler's diarrhea. Loperamide is a piperadine derivative that slows intestinal motility because of its activation of m-opiate receptors. By decreasing peristalsis and increasing anal sphincter tone, it increases intestinal transit time, thus retaining luminal contents and giving more time for reabsorption of secreted fluid. The drug has a less prominent effect through inhibition of intestinal secretion by its action on G 1 -linked receptors to counter increases in cyclic adenosine monophosphate caused by bacterial enterotoxins. It is available over the counter as a diarrheal remedy and has been recommended for traveler's diarrhea for 125 years [2] . A newer form of the drug, loperamide oxide, was tested in Germany and was shown to be more effective than placebo against diarrhea [3] . Its advantage, as a prodrug that is changed to loperamide by anaerobic bacteria in the intestine, is to give more-prolonged and higher drug concentrations in the intestinal lumen, with less absorption into the blood, potentially causing fewer systemic adverse effects, such as CNS depression, than when loperamide hydrochloride is administered.
Clinical studies in the meta-analysis enrolled young US students or military personnel in prospective randomized trials in Mexico, Thailand, and Egypt. The most common microbial cause of diarrhea identified in study participants were enterotoxigenic Escherichia coli, followed by Shigella species, Campylobacter species, Salmonella species, enteroaggregative E. coli, Giardia lamblia, Entamoeba histolytica, and Cryptosporidium species. Pathogenesis of traveler's diarrhea occurs at the epithelial cell surface of the intestine, where enterotoxins cause fluid production or invasive pathogens elicit inflammation. Neural signals are transmitted from this surface to smooth muscle to increase peristalsis, giving rise to symptoms of cramps and frequent bowel movements. Traveler's diarrhea is unique for a high attack rate because of a low level of immunity in travelers against prevalent pathogens in the food and water from the visited countries. Travelers are also a selected population of usually young, healthy adults who develop mild or moderately severe nondehydrating illnesses that do not require hospitalization. They do not die as young children and malnourished inhabitants of developing countries sometimes do when infected with the same pathogens, and the travelers usually recover in a few days, even when treated with placebo [4] . Although initially not immune against local pathogens, travelers mount effective immune responses that are instrumental in their recoveries from self-limited illness. Absence of significant dehydration in most cases was demonstrated in a randomized trial of oral rehydration solutions in addition to loperamide, which showed no benefit of oral rehydration solutions to hasten recovery from symptomatic illness [5] .
Trials in the analysis pertinently compared treatments of loperamide hydrochloride plus an antimicrobial drug with the same antimicrobial drug alone. Most of the analyzed studies reported that loperamide conferred a substantial benefit by reducing frequency of loose stools by approximately one-half and by shortening the average duration of diarrhea from ∼1.5 days to !1 day, with a range of mean reductions of duration of 2-23 h. How broadly applicable are these results to all diarrheal illness in travelers and other persons? Two studies in the analysis were partly discordant with regard to beneficial action: patients with Campylobacter infection in Thailand, where these infections showed fluoroquinolone resistance [6] , and patients with Shigella infections in Mexico [7] showed no benefit from loperamide. Antimicrobial drugs without loperamide reduced diarrheal duration by approximately one-half when compared with placebo, as was demonstrated for trimethoprim-sulfamethoxazole in Mexico [4] . When used alone, loperamide reduces the duration of diarrhea and the frequency of bowel movements, compared with placebo [4, 8] but has less effect than in combination with an antimicrobial drug [4, 9] . In countries visited by travelers, children who have not yet acquired immunity to enterotoxigenic E. coli are susceptible to disease, but children !6 years of age are not advised to receive loperamide because of potential overdoses that could cause CNS depression. Patients with bloody diarrhea or high temperatures were excluded from the analyzed studies. It is not known whether loperamide therapy will be effective against diarrhea caused by norovirus, the most common cause of outbreaks of nonbacterial gastroenteritis worldwide [10] .
The analyzed studies, nevertheless, were soundly designed as prospective and randomized studies, with most using loperamide placebos in a double-blind manner. An unavoidable fault of the study methods was quantitative imprecision, because the studies used patients' self-reported frequency of stools and time since their last unformed stools. These data were subjective, according to different perceptions of what constitutes an unformed stool. Another problem, perhaps related to subjective reporting of symptoms, is heterogeneity of enrolled patients' responses to loperamide. In 4 separate studies of students in Mexico, the mean and median durations of diarrhea after the start of loperamide therapy had a range of 0-27 h.
A conclusion from the analyzed trials is that loperamide should be combined narrowly with an antimicrobial drug for travelers to areas where enterotoxigenic E. coli is anticipated to be the major diarrheal pathogen. Loperamide should not be regarded as a broad empirical fix, because it does not benefit patients with excessive diarrhea, such as those with cholera, and should not be used to treat bloody dysentery; patients with Shigella or Campylobacter infection may not derive any benefit from the drug, but they seem not to be harmed by it. What explains the drug's success? It works especially well in lowvolume secretory diarrhea, probably because a decrease in peristalsis and an increase in anal sphincter tone causes retention of secreted fluid, giving more time for intestinal mucosa distal to secretion sites to reabsorb excess luminal fluid. Reduced peristalsis also diminishes fecal urgency and frequency of bowel movements. It makes mild or moderately severe diarrhea even milder. A healthy distal colon absorbs water and salt avidly and should be the major site of absorption of additional fluid presented to it during secretory diarrhea. Shigella and Campylobacter species cause primarily distal colitis, whereas enterotoxigenic E. coli affects the small intestine; therefore, impaired absorption in the colon may explain refractoriness of infection due to Shigella and Campylobacter when treated with loperamide [11] . Although loperamide should continue to be used by travelers, priority should be placed on selecting an appropriate antimicrobial to be combined with it. This selection will burden practitioners of travel medicine to be familiar with prevalent microbes in different countries and their antimicrobial susceptibilities.
